Key facts
- Alantos Pharmaceuticals Holding’s last known valuation is $300.0M (Jul 2007).
- It has raised $67.3M; the latest was PE Growth/Expansion in Jun 2025.
- Notable investors include Industrial Innovation Partners.
- Status: Acquired/Merged.
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Alantos Pharmaceuticals Holding
- ·The full record, as it builds
Funding rounds
No funding rounds for Alantos Pharmaceuticals Holding are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alantos Pharmaceuticals Holding
Developer of drugs intended for the treatment of diabetes and inflammatory diseases. The company specializes in a broad proprietary pipeline of small-molecule drugs focused on proteases that impact Type II diabetes and osteoarthritis, and inflammation, enabling scientists to rapidly identify proprietary compounds for key targets in biologically validated pathways.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 1999
- Website
- alantos.com/
- Ownership
- Acquired/Merged
Alantos Pharmaceuticals Holding doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alantos Pharmaceuticals Holding shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alantos Pharmaceuticals Holding in its N-PORT filings yet. We sweep new filings monthly.